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1. Introduction
  Liver fibrosis is a process with liver cell degeneration 
necrosis due to various pathogenic factors and hepatic 
fibrous tissue excessive deposition[1-3]. Hepatic fibrosis 
is the early stage of liver cirrhosis which yet is the only 
reversible stage, and liver fibrosis is one of the important 
pathological features of chronic liver disease as a main 
intermediate link to the development of liver cirrhosis, 
and if this is persist, it is quite likely to develop into liver 
cirrhosis, followed by liver cancer[4]. Liver cancer is the 
top lethal cause among tumors, which threats the patient’s 
life and health seriously, so it is significant for prevention 
of liver cirrhosis to block its pathological development of 
liver fibrosis stage[5]. Research has shown that a variety 
of cytokines and inflammatory mediators are related to 
liver fibrosis, and interaction of these cytokines forms a 
complex network, playing a key role in the formation of 
liver fibrosis[6]. The anti fibrosis effect of 毭-interferon 
has gained clinically common approval, andAASLD has 
officially recommended it as the drug of first choice for 
liver fibrosis[7]. But the shortcomings as short half-life, 
antibodies induction and serious side effects due to a 
large dose limits its clinical application. Matrine has made 
certain achievements in the prevention and treatment of 
Objective: To observe the preventive and control effect of matrine on transforming growth factor 
(TGF-毬1) and hepatocyte growth factor (HGF) of liver fibrosis tissue in rats. Methods: A total of 
48 SD rats were randomly divided into A, B, C, D groups with 12 in each, group A as the normal 
control group and groups B, C, D as liver fibrosis models using composite modulus method with 
carbon tetrachloride (CCL4). Group B was the model group, group C adopted γ- interferon lavage 
therapy in the second day of modeling, and group D adopted matrine lavage treatment, at 4 and 
8 weeks after treatment. Six rats were executed for detection of TGF-毬1 and HGF, liver tissue 
histology and comparison fibrosis degree changes of rat liver tissue between groups. Results: 
Groups B, C, D showed a more significantly increased TGF-毬1 at each time point compared with 
group A (P<0.05); Group B showed a more significantly increased TGF-毬1 than groups C and D 
at weeks 4 and 8 (P<0.05); group D showed a lowest level of TGF-毬1, followed by groups C and 
B. HGF of group B decreased more significantly than A group at weeks 4 and 8 (P<0.05); HGF 
of groups C and D was significantly elevated at 4 and 8 weeks than groups A and B (P<0.05), in 
which the group D showed the highest level of HGF. According to tissue histologic observation, rat 
liver tissue structure of group A was clear and normal, tissue structure of group B was destroyed 
with obvious fibrous tissue hyperplasia and fatty change of hepatic cells; groups C and D showed 
a slighter liver tissue damage, cell necrosis and connective tissue hyperplasia in collect abbacy 
than group B with a trend of obvious improvement. Conclusions: Matrine can reduce TGF-毬1 
expression and enhance the activity of HGF, so as to realize the inhibition effect on liver fibrosis 
in rats.
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fibrosis in recent years, with a good application prospect. 
Modern pharmacology study has shown that curative effect of 
matrine on tissue fibrosis treatment is distinct[8]. To observe 
the preventive and control effect of matrine on liver fibrosis, 
this research set up rat liver fibrosis models using composite 
modulus method with carbon tetrachloride[9], combined with 
毭-interferon and matrine therapy in the modeling. The 
expression of TGF-毬1 and HGF as well as histological cell 
change were studied.
2. Materials and methods
2.1. Experimental animals
  A total of 48 male SD rats (clean level of class II, age of 
8-10 weeks) weighing (151.3±22.5) g were provided by the 
laboratory animal center. They were free for access to food 
and water. Experiment processes on animals strictly followed 
the “Administration Regulations on the Experimental 
Animals”.
2.2. Instruments and reagents
  CCL4 was provided by Tianjin Fine Chemical Research 
Institute. Matrine was provided by Nanjing Zinze Science 
And Technology Development Company. Restructuring 毭
-interferon and olive oil for experimental use were provided 
with Lizhu Biological Engineering Pharmaceutical Factory. 
Mouse anti-human TGF-毬 monoclonal antibody and 
mouse anti-human HGF monoclonal antibody were provided 
by Beijing Boaosen Biological Technology Co., LTD. RT-
PCR one-step kit, tissue DNA extraction kit and TRIZOL 
reagent were manufactured by Beijing BioTeke Biological 
Technology Co., LTD. S-3000N scanning electron microscope 
was provided by HITACHI Company (Japan), and 5804 
centrifuges were provided by Eppendorf Company. Tissue 
array instrument and gel imaging analysis system were 
provided by Beecher Instruments Company (USA), and CS-
930 TLC scanner was manufactured in Japan.
2.3. Animal model establishment and grouping
  A total of 48 SD rats were randomly divided into groups A, 
B, C, D with 12 in each, group A as the normal control group, 
groups B, C, D as liver fibrosis models using composite 
modulus method with CCL4. Subcutaneous injection of 6 mL/kg 
CCL4 analytical pure concentrate reagent was adopted in 
initial stage of modeling, then every 3 days after modeling 
initiation added CCL4 olive oil mixture 3 mL/kg sc., and from 
2 weeks after modeling, adding 0.5 mL/100 g alcohol (25%) for 
intragastric administration once a day. Group A was treated 
with equivalent amount of normal saline lavage, group B 
was the model control group without any processing after 
modelling, group C adopted 毭-interferon 0.2 mu/kg lavage 
therapy in the second day of modeling once a day, and group 
D adopted matrine 100 mg/kg lavage treatment in the second 
day of modeling once a day. All groups of rats were fed with 
high-fat diet.
2.4. Experimental method
  At 4 and 8 weeks after treatment, six rats of each group 
were executed, using Western blot method for detection 
of rat liver tissue TGF-毬1 and HGF mRNA expression. 
And liver tissue specimen was taken for HE staining to 
observe issue morphology at 8 weeks after modeling and 
observation. After intraperitoneal injection of 10% chloral 
hydrate anesthesia, extracted the middle of liver tissue 
by caesarean section, soaked liver middle small blocks in 
10% of formaldehyde solution for fixation; water rinsed for 
2 h, processed the specimen using automatic dewatering 
machine for biological tissue dehydration and transparent, 
procedure was strictly according to operating instructions. 
Cut specimen into 5 毺m slice and put in oven bake at 
40 曟 for 1 h, xylene skim was used for 10 min, followed 
by conventional gradient alcohol dehydration, made the 
tissue blue by using distilled water hydration for 5 min, 
hematoxylin staining for 15 min, and water flushing for
1 min; 1% of hydrochloric acid ethanol for color separation 
was used for 1 min to make slice red, water rinsed for
30 min, different gradient ethanol for dehydration was used 
for 5 min, 95% eosin ethanol for color separation was used 
for 2 min, 100% ethanol I, II for dehydration was used for
2 min. Used xylene for transparency, neutral resin for 
sliding, and microscope for observation histological changes.
2.5. Result determination
  UVP type gel image analysis system was applied to analyze 
integral absorbance measurement of the bands in Western 
blot-electrophoresis method; absorbance ratio of each group 
of genes with internal reference control gene was used to 
determine the differences of mRNA expression. The mRNA 
expression intensity = Absorbance density value of samples 
target mRNA/Absorbance density value of corresponding
毬-actin mRNA.
2.6. Statistical analysis 
  SPSS 19.0 statistical software was used for processing the 
group data with t test, and measurement data were expressed 
in (Mean±SD). P<0.05 for the difference was statistically 
significant.
3. Results
3.1. TGF-毬1 and HGF expression at each time point among 
groups 
  TGF-毬1 in B, C and D groups was significantly higher 
than that in group A at each time point (P<0.05). Group D 
showed the lowest level of TGF-毬1, followed by groups C 
and B. HGF in group B decreased more significantly than 
that in group A at weeks 4 and 8 (P<0.04). HGF in groups C 
and D was elevated more significantly than that in groups A 
and B at weeks 4 and 8 (P<0.05), in which group D showed 
the highest level of HGF. The results are shown in Table 1.
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3.2. Tissue histologic changes observation among groups 
  The rat liver tissue structure in group A was clear 
without cell degeneration or necrosis, and liver cell line 
arrangement is neat with uniform cell. Tissue structure 
of group B was destroyed with obvious fibrous tissue 
hyperplasia, disappeared lobular structures and liver cell 
cord derangement, as well as fatty change or ballooning 
degeneration of hepatic cells, and severe infiltration of 
inflammatory cells was observed around the central vein and 
manifold. Compared with group B, groups C and D showed 
a slighter liver tissue damage, cell necrosis and connective 
tissue hyperplasia in collect abbacy with a trend of obvious 
improvement (Figure 1). The liver fibrosis histologic changes 
of four groups were analyzed using semi-quantitative 
scoring statistics (SSS). SSS score is 0 for group A, 11.62±1.56 
for group B, 7.59±0.80 for group C and 7.43±0.70 for group 
D. SSS scores of groups B, C and D were significantly higher 
than that of group A (P<0.05). Scores of groups C and D were 
significantly lower than that of group B (P<0.05). There was 
no statistical significant differences in SSS scores between 
groups C and D.
(A) Group A                                              (B) Group B
(C) Group C                                              (D) Group D
Figure 1. Tissue histologic changes of rats with liver fibrosis after 
treatment with matrine (HE, ×20).
4. Discussion
  Liver fibrosis is the repair reaction of liver of chronic 
damage and is also a rite among development and 
progression of a variety of chronic liver diseases. Of 
patients with liver fibrosis, 25%-40% eventually develop 
into liver cirrhosis and liver cancer[10]. Studies have shown 
that process of liver fibrosis can be reversed[11-13], so the 
reverse process of liver fibrosis is of great significance to 
block the formation of liver cancer. CCL4 can dissolve the 
liver cell membrane, directly by the metabolism of liver 
cell cytochrome, start the lipid peroxidation of liver cells, 
and cause liver cell damage. It is the most widely used 
toxic chemical for inducing liver fibrosis experiments[14-
16]. Commonly used liver fibrosis model induced methods 
are CCL4 simple method and CCL4 complex method, with 
respective advantages and disadvantages[17]. The composite 
method is adopted to establish the experimental rat liver 
fibrosis model. First, CCL4 analysis pure concentrate 6 mL/kg was 
adopted by subcutaneous injection. Then, 3 days later, 3 mL/kg
of 50% agents with 1:1 olive oil and CCL4 sc. was used. A 
week later, 25% alcohol was used to lavage the rats. All the 
groups of rats were fed on a high-fat diet. After 4 weeks, 
tissue structure of group B was destroyed with obvious 
fibrous tissue hyperplasia and liver cell cord derangement, 
as well as fatty change or ballooning degeneration of hepatic 
cells, and severe infiltration of inflammatory cells was 
observed around the central vein and manifold, showing 
that the composite modeling method is faster, more reliable 
and effective than the simple modeling method. Histological 
observation in this study showed, according to the modeling 
results after 8 weeks, liver damage, liver cell edema, 
extent of ballooning degeneration, liver cell necrosis, and 
collect abbacy connective tissue hyperplasia of group D 
were reduced more significantly compared with groups B. 
Liver tissue damage of groups C and  D had no significant 
diferences, indicating matrine can obviously improve 
abnormal liver fibrosis tissue structure and effectively 
alleviate liver cell injury.
  Studies have found that TGF-毬1 is the most important 
role in fibrosis factor, participating in the liver fibrosis 
process, and closely related to occurrence and development 
of liver fibrosis[18-20]. In this study, quantity of TGF-毬1
expressed in groups B, C and D was significantly higher 
than that in group A, which is consistent with the previous 
result[19]. Groups C and D showed a significantly reduced 
trend of TGF-毬1 expression than group B, suggesting that 
毭-interferon and matrine have inhibitory effect on TGF-毬1
protein expression at the mRNA and protein level. This 
plays a role in anti-liver fibrosis. HGF has many kinds 
of biological functions, such as promoting liver function 
Table 1
Expression levels of TGF-毬1 and HGF in rat liver fibrosis model treated with matrine (n=12). 
Group Treatment
TGF-毬1 HGF
4 weeks 8 weeks 4 weeks 8 weeks
Group A Normal saline 0.84依0.07 0.91依0.09 1.06依0.09 1.11依0.09
Group B No treatment 1.44依0.11 1.68依0.15 0.81依0.08 0.88依0.09
Group C 0.2 mu/kg 毭-interferon 1.00依0.08 1.17依0.09 1.23依0.06 1.51依0.10
Group D 100 mg/kg matrine 0.96依0.06 1.15依0.11 1.27依0.09 1.58依0.15
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recovery and alleviating liver fibrosis[20,22]. Studies have 
shown that HGF is a powerful stimulant for liver cell growth 
and DNA synthesis[23,24]. HGF can inhibit fibrosis, decrease 
the expression of collagen, and promote the degradation of 
extracellular matrix. In CCL4 toxicity model, a significant 
rise in early HGF mRNA showed that CCL4 caused liver 
cell damage at the same time. HGF is highly expressed 
for promoting liver regeneration and repairment[25]. In this 
study, HGF expression level in group B was lower than 
that in group A (P<0.05), suggesting that HGF expression 
decreased in the liver fibrosis tissue. HGF content of groups 
C and D increased (P<0.05), showing that 毭-interferon 
and matrine can raise the expression of HGF in liver tissue, 
so as to play a role in resisting liver fibrosis. The results 
confirmed that TGF-毬1 and HGF have antagonistic effect of 
cell factor. The results showed that HGF of group B was with 
low expression, but the expression of TGF-毬1 was high. 
Expression of TGF-毬1 and HGF in groups C and D were the 
opposite to that of group B. TGF-毬1 cytokines plays a very 
important role in fibrosis disease, so the antagonism of its 
biological effect is of great significance[26].
  Matrine can reduce TGF-毬1 expression and enhance the 
activity of HGF, so as to realize the inhibition effect on liver 
fibrosis in rats.
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